Lumeva · MIG · Spain · Headache specialist · captured by Luis Ortega on 22 Jul 2026 · reviewed by Dr. Elena Moretti on 25 Jul 2026
Verbatim as captured; never edited
Headache specialist at Vall d'Hebron said around 40% of her chronic migraine patients have concurrent medication-overuse headache and that no CGRP antagonist trial has included them meaningfully. She would be interested in an investigator-initiated study.
Human-approved by Dr. Elena Moretti on 25 Jul 2026
Interest in IIS on lumevarin in chronic migraine with medication-overuse headache; population under-represented in trials.
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 4 | 20% | 16.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 2 | 15% | 6.0 |
| Novelty | 4 | 10% | 8.0 |
| Actionability | 4 | 10% | 8.0 |
| Confidence | 4 | 5% | 4.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | High 72 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
22 Jul 2026 · Dr. Paola Castellano, Vall d'Hebron · MSL Luis Ortega
Insight
Reviewed 25 Jul 2026 by Dr. Elena Moretti
HEOR · Dr. Nikolai Petrov · due 31 Oct 2026 · In progress
Initiative
Decision
Outcome
Study · EVP-0009
Closure
27 Apr 2026 · DE · MSL interaction